跳至主要内容
临床试验/NCT00584766
NCT00584766已完成2 期

Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study

University of Oklahoma2 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2008年1月2日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
21
试验地点
2
主要终点
Quality of maximal response; time to initial disease progression; and overall survival

研究概览

简要总结

To determine the therapeutic efficacy of high-dose cyclophosphamide and BCNU with autologous bone marrow transplantation after initial tumor cytoreduction for patients with receptor-negative metastatic breast carcinoma and to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast carcinoma

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • breast carcinoma at first clinical evidence of metastatic disease
  • must have measurable disease by physical exam, x-ray, or scan
  • Age < or equal to 55
  • performance status 0-2

排除标准

  • can't have had more than one prior chemotherapy regimen
  • can't have had concurrent hormonal therapy
  • no brain metastases
  • no previous pelvic radiation
  • no history of another malignancy

结局指标

主要结局

Quality of maximal response; time to initial disease progression; and overall survival

时间窗: undetermined

次要结局

  • to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast cancer(undetermined)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验